{"id":"347cf1c8-22c8-5e4e-b59e-4b6989c4a8da","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-mouse-zo1","predicate":"increases_in_recorded_comparison","statement":"RA pretreatment mitigated loss of ZO-1 expression during the E. coli challenge.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"3d92432a-fe45-541d-8ef3-d1c7aea2188d","mechanism_event_label":"RA pretreatment mitigated loss of ZO-1 expression during the E. coli challenge.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"d861d59a-bb0d-55e8-8271-4b97c327d8de","slug":"mouse-tjp1","display_name":"Mouse tight-junction protein ZO-1 / Tjp1","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"3d92432a-fe45-541d-8ef3-d1c7aea2188d","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-mouse-zo1-event","event_type":"experimental_observation","label":"RA pretreatment mitigated loss of ZO-1 expression during the E. coli challenge.","description":"### ra-mouse-zo1\n\nRA pretreatment mitigated loss of ZO-1 expression during the E. coli challenge.\nThe abstract has contradictory permeability wording, so no quantitative permeability claim is assigned.\nModel and exposure: Mice: oral 20 mg/kg for one week before intraperitoneal challenge; accompanying mouse epithelial-cell experiments.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Rosmarinic acid alleviated intestinal barrier damage caused by <i>Escherichia coli</i> by regulating the gut microbiota and inhibiting the NF-κB signalling pathway in mice. | 2024 | https://pubmed.ncbi.nlm.nih.gov/39540591/ | https://doi.org/10.1039/d4fo02654c | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"RA pretreatment plus bacterial challenge","sequence_order":0,"notes":""},{"entity":{"id":"d861d59a-bb0d-55e8-8271-4b97c327d8de","slug":"mouse-tjp1","display_name":"Mouse tight-junction protein ZO-1 / Tjp1","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA pretreatment plus bacterial challenge\", \"comparator\": \"Bacterial challenge alone\", \"endpoint\": \"RA pretreatment mitigated loss of ZO-1 expression during the E. coli challenge.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Mice: oral 20 mg/kg for one week before intraperitoneal challenge; accompanying mouse epithelial-cell experiments.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"RA pretreatment mitigated loss of ZO-1 expression during the E. coli challenge.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Rosmarinic acid alleviated intestinal barrier damage caused by <i>Escherichia coli</i> by regulating the gut microbiota and inhibiting the NF-κB signalling pathway in mice. | https://pubmed.ncbi.nlm.nih.gov/39540591/ | https://doi.org/10.1039/d4fo02654c","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-mouse-zo1; The abstract has contradictory permeability wording, so no quantitative permeability claim is assigned.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"4c5a55fc-4d14-5623-b270-86809a532274","evidence_kind":"source_excerpt","locator":"Lines 546-552","start_line":546,"end_line":552,"excerpt":"### ra-mouse-zo1\n\nRA pretreatment mitigated loss of ZO-1 expression during the E. coli challenge.\nThe abstract has contradictory permeability wording, so no quantitative permeability claim is assigned.\nModel and exposure: Mice: oral 20 mg/kg for one week before intraperitoneal challenge; accompanying mouse epithelial-cell experiments.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Rosmarinic acid alleviated intestinal barrier damage caused by <i>Escherichia coli</i> by regulating the gut microbiota and inhibiting the NF-κB signalling pathway in mice. | 2024 | https://pubmed.ncbi.nlm.nih.gov/39540591/ | https://doi.org/10.1039/d4fo02654c | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Mice: oral 20 mg/kg for one week before intraperitoneal challenge; accompanying mouse epithelial-cell experiments.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}